Do analysts rate OBIO or POCI?

Orchestra BioMed currently has a consensus price target of $13.60, indicating a potential upside of 234.15%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, equities research analysts clearly believe Orchestra BioMed is more favorable than Precision Optics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Orchestra BioMed 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Precision Optics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend POCI or TMCI?

Treace Medical Concepts has a consensus price target of $4.77, suggesting a potential upside of 21.99%. Given Treace Medical Concepts' stronger consensus rating and higher probable upside, analysts plainly believe Treace Medical Concepts is more favorable than Precision Optics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precision Optics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Treace Medical Concepts 2 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.86

Does the media prefer POCI or TMCI?

In the previous week, Treace Medical Concepts had 2 more articles in the media than Precision Optics. MarketBeat recorded 4 mentions for Treace Medical Concepts and 2 mentions for Precision Optics. Treace Medical Concepts' average media sentiment score of 1.87 beat Precision Optics' score of 0.94 indicating that Treace Medical Concepts is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precision Optics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Treace Medical Concepts 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer PDEX or POCI?

Pro-Dex currently has a consensus price target of $70.00, indicating a potential upside of 11.25%. Given Pro-Dex's stronger consensus rating and higher probable upside, equities analysts plainly believe Pro-Dex is more favorable than Precision Optics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pro-Dex 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Precision Optics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, PDEX or POCI?

Pro-Dex has higher revenue and earnings than Precision Optics. Precision Optics is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pro-Dex $66.59M 3.01 $8.98M $3.62 17.38 Precision Optics $19.09M 3.31 -$5.78M -$0.63 N/A

Is PDEX or POCI more profitable?

Pro-Dex has a net margin of 16.08% compared to Precision Optics' net margin of -17.03%. Pro-Dex's return on equity of 22.78% beat Precision Optics' return on equity. Company Net Margins Return on Equity Return on Assets Pro-Dex 16.08% 22.78% 14.30% Precision Optics -17.03% -37.47% -19.96%

Does the media favor PDEX or POCI?

In the previous week, Pro-Dex and Pro-Dex both had 2 articles in the media. Pro-Dex's average media sentiment score of 1.07 beat Precision Optics' score of 0.94 indicating that Pro-Dex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pro-Dex 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precision Optics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend POCI or RXST?

RxSight has a consensus target price of $9.44, suggesting a potential upside of 96.76%. Given RxSight's stronger consensus rating and higher possible upside, analysts plainly believe RxSight is more favorable than Precision Optics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precision Optics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 RxSight 3 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.93

Is POCI or RXST more profitable?

Precision Optics has a net margin of -17.03% compared to RxSight's net margin of -36.58%. RxSight's return on equity of -17.01% beat Precision Optics' return on equity. Company Net Margins Return on Equity Return on Assets Precision Optics -17.03% -37.47% -19.96% RxSight -36.58% -17.01% -15.12%

Precision Optics (POCI) Competitors

$5.77 +0.12 (+2.12%)

Closing price 04:00 PM Eastern

Extended Trading

$5.78 +0.02 (+0.26%)

As of 04:10 PM Eastern

Compare

POCI vs. OBIO, TMCI, PDEX, STEX, and RXST

Should you buy Precision Optics stock or one of its competitors? MarketBeat compares Precision Optics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Precision Optics include Orchestra BioMed (OBIO), Treace Medical Concepts (TMCI), Pro-Dex (PDEX), Biosig Technologies (STEX), and RxSight (RXST). These companies are all part of the "medical equipment" industry.

How does Precision Optics compare to Orchestra BioMed?

Orchestra BioMed (NASDAQ:OBIO) and Precision Optics (NASDAQ:POCI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Precision Optics has a net margin of -17.03% compared to Orchestra BioMed's net margin of -166.96%. Precision Optics' return on equity of -37.47% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-166.96%	-157.46%	-60.18%
Precision Optics	-17.03%	-37.47%	-19.96%

Orchestra BioMed has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, Precision Optics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

53.2% of Orchestra BioMed shares are owned by institutional investors. Comparatively, 13.7% of Precision Optics shares are owned by institutional investors. 7.5% of Orchestra BioMed shares are owned by insiders. Comparatively, 14.4% of Precision Optics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Precision Optics has lower revenue, but higher earnings than Orchestra BioMed. Precision Optics is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$32.72M	7.45	-$52.70M	-$0.97	N/A
Precision Optics	$19.09M	3.31	-$5.78M	-$0.63	N/A

Orchestra BioMed currently has a consensus price target of $13.60, indicating a potential upside of 234.15%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, equities research analysts clearly believe Orchestra BioMed is more favorable than Precision Optics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Precision Optics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Precision Optics had 1 more articles in the media than Orchestra BioMed. MarketBeat recorded 2 mentions for Precision Optics and 1 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 1.22 beat Precision Optics' score of 0.94 indicating that Orchestra BioMed is being referred to more favorably in the media.

Company	Overall Sentiment
Orchestra BioMed	Positive
Precision Optics	Positive

Summary

Orchestra BioMed beats Precision Optics on 9 of the 16 factors compared between the two stocks.

How does Precision Optics compare to Treace Medical Concepts?

Precision Optics (NASDAQ:POCI) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

In the previous week, Treace Medical Concepts had 2 more articles in the media than Precision Optics. MarketBeat recorded 4 mentions for Treace Medical Concepts and 2 mentions for Precision Optics. Treace Medical Concepts' average media sentiment score of 1.87 beat Precision Optics' score of 0.94 indicating that Treace Medical Concepts is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precision Optics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Treace Medical Concepts	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Treace Medical Concepts has a consensus price target of $4.77, suggesting a potential upside of 21.99%. Given Treace Medical Concepts' stronger consensus rating and higher probable upside, analysts plainly believe Treace Medical Concepts is more favorable than Precision Optics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision Optics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86

13.7% of Precision Optics shares are held by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are held by institutional investors. 14.4% of Precision Optics shares are held by insiders. Comparatively, 23.4% of Treace Medical Concepts shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Precision Optics has higher earnings, but lower revenue than Treace Medical Concepts. Precision Optics is trading at a lower price-to-earnings ratio than Treace Medical Concepts, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision Optics	$19.09M	3.31	-$5.78M	-$0.63	N/A
Treace Medical Concepts	$212.69M	1.19	-$59M	-$0.97	N/A

Precision Optics has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Treace Medical Concepts has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

Precision Optics has a net margin of -17.03% compared to Treace Medical Concepts' net margin of -29.44%. Precision Optics' return on equity of -37.47% beat Treace Medical Concepts' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision Optics	-17.03%	-37.47%	-19.96%
Treace Medical Concepts	-29.44%	-67.04%	-30.28%

Summary

Treace Medical Concepts beats Precision Optics on 10 of the 16 factors compared between the two stocks.

How does Precision Optics compare to Pro-Dex?

Pro-Dex (NASDAQ:PDEX) and Precision Optics (NASDAQ:POCI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Pro-Dex has a net margin of 16.08% compared to Precision Optics' net margin of -17.03%. Pro-Dex's return on equity of 22.78% beat Precision Optics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	16.08%	22.78%	14.30%
Precision Optics	-17.03%	-37.47%	-19.96%

In the previous week, Pro-Dex and Pro-Dex both had 2 articles in the media. Pro-Dex's average media sentiment score of 1.07 beat Precision Optics' score of 0.94 indicating that Pro-Dex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pro-Dex	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precision Optics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pro-Dex currently has a consensus price target of $70.00, indicating a potential upside of 11.25%. Given Pro-Dex's stronger consensus rating and higher probable upside, equities analysts plainly believe Pro-Dex is more favorable than Precision Optics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Precision Optics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pro-Dex has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market. Comparatively, Precision Optics has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

Pro-Dex has higher revenue and earnings than Precision Optics. Precision Optics is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$66.59M	3.01	$8.98M	$3.62	17.38
Precision Optics	$19.09M	3.31	-$5.78M	-$0.63	N/A

15.3% of Pro-Dex shares are held by institutional investors. Comparatively, 13.7% of Precision Optics shares are held by institutional investors. 45.9% of Pro-Dex shares are held by company insiders. Comparatively, 14.4% of Precision Optics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Pro-Dex beats Precision Optics on 13 of the 15 factors compared between the two stocks.

How does Precision Optics compare to Biosig Technologies?

Biosig Technologies (NASDAQ:STEX) and Precision Optics (NASDAQ:POCI) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

Biosig Technologies presently has a consensus price target of $8.00, indicating a potential upside of 740.25%. Given Biosig Technologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe Biosig Technologies is more favorable than Precision Optics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Precision Optics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biosig Technologies has a net margin of 0.00% compared to Precision Optics' net margin of -17.03%. Precision Optics' return on equity of -37.47% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
Precision Optics	-17.03%	-37.47%	-19.96%

Biosig Technologies has a beta of 1.85, indicating that its share price is 85% more volatile than the broader market. Comparatively, Precision Optics has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Precision Optics has higher revenue and earnings than Biosig Technologies. Precision Optics is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	4,327.29	-$462.77M	-$9.71	N/A
Precision Optics	$19.09M	3.31	-$5.78M	-$0.63	N/A

In the previous week, Precision Optics had 1 more articles in the media than Biosig Technologies. MarketBeat recorded 2 mentions for Precision Optics and 1 mentions for Biosig Technologies. Biosig Technologies' average media sentiment score of 1.89 beat Precision Optics' score of 0.94 indicating that Biosig Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Biosig Technologies	Very Positive
Precision Optics	Positive

7.2% of Biosig Technologies shares are held by institutional investors. Comparatively, 13.7% of Precision Optics shares are held by institutional investors. 52.7% of Biosig Technologies shares are held by company insiders. Comparatively, 14.4% of Precision Optics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Biosig Technologies beats Precision Optics on 9 of the 16 factors compared between the two stocks.

How does Precision Optics compare to RxSight?

Precision Optics (NASDAQ:POCI) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

13.7% of Precision Optics shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 14.4% of Precision Optics shares are owned by insiders. Comparatively, 10.1% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Precision Optics has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, RxSight has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

Precision Optics has higher earnings, but lower revenue than RxSight. Precision Optics is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision Optics	$19.09M	3.31	-$5.78M	-$0.63	N/A
RxSight	$134.48M	1.48	-$38.94M	-$1.13	N/A

Precision Optics has a net margin of -17.03% compared to RxSight's net margin of -36.58%. RxSight's return on equity of -17.01% beat Precision Optics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision Optics	-17.03%	-37.47%	-19.96%
RxSight	-36.58%	-17.01%	-15.12%

In the previous week, Precision Optics had 1 more articles in the media than RxSight. MarketBeat recorded 2 mentions for Precision Optics and 1 mentions for RxSight. RxSight's average media sentiment score of 1.89 beat Precision Optics' score of 0.94 indicating that RxSight is being referred to more favorably in the news media.

Company	Overall Sentiment
Precision Optics	Positive
RxSight	Very Positive

RxSight has a consensus target price of $9.44, suggesting a potential upside of 96.76%. Given RxSight's stronger consensus rating and higher possible upside, analysts plainly believe RxSight is more favorable than Precision Optics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision Optics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93

Summary

RxSight beats Precision Optics on 10 of the 16 factors compared between the two stocks.

Get Precision Optics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding POCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

POCI vs. The Competition

Export

Metric	Precision Optics	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$63.12M	$7.07B	$6.51B	$11.99B
Dividend Yield	N/A	1.20%	2.67%	5.62%
P/E Ratio	-9.16	48.13	24.24	24.13
Price / Sales	3.31	45.90	473.68	84.94
Price / Cash	N/A	25.48	43.05	54.72
Price / Book	3.61	6.91	10.49	6.82
Net Income	-$5.78M	$159.22M	$3.56B	$337.52M
7 Day Performance	4.34%	-4.54%	-2.02%	-0.96%
1 Month Performance	28.51%	4.59%	0.66%	1.68%
1 Year Performance	18.97%	-2.02%	21.85%	26.88%

Precision Optics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
POCI Precision Optics	0.5991 of 5 stars	$5.77 +2.1%	N/A	+20.7%	$63.12M	$19.09M	N/A	80
OBIO Orchestra BioMed	4.2111 of 5 stars	$4.02 +4.0%	$13.60 +238.7%	+20.4%	$240.36M	$33.48M	N/A	4
TMCI Treace Medical Concepts	2.7256 of 5 stars	$3.63 +6.6%	$4.77 +31.6%	-31.4%	$235.80M	$212.69M	N/A	250	Positive News Insider Trade
PDEX Pro-Dex	3.2743 of 5 stars	$67.64 +3.8%	$70.00 +3.5%	+46.7%	$215.85M	$74.64M	18.67	140	News Coverage Positive News
STEX Biosig Technologies	2.8902 of 5 stars	$1.20 +11.7%	$8.00 +569.5%	N/A	$215.43M	$40K	N/A	50	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:POCI) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Precision Optics (POCI) Competitors

POCI vs. OBIO, TMCI, PDEX, STEX, and RXST

How does Precision Optics compare to Orchestra BioMed?

Summary

How does Precision Optics compare to Treace Medical Concepts?

Summary

How does Precision Optics compare to Pro-Dex?

Summary

How does Precision Optics compare to Biosig Technologies?

Summary

How does Precision Optics compare to RxSight?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

POCI vs. The Competition

Precision Optics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Precision Optics (POCI) Competitors

POCI vs. OBIO, TMCI, PDEX, STEX, and RXST

How does Precision Optics compare to Orchestra BioMed?

Is OBIO or POCI more profitable?

Which has more volatility and risk, OBIO or POCI?

Do institutionals and insiders believe in OBIO or POCI?

Which has preferable valuation & earnings, OBIO or POCI?

Do analysts rate OBIO or POCI?

Does the media refer more to OBIO or POCI?

Summary

How does Precision Optics compare to Treace Medical Concepts?

Does the media prefer POCI or TMCI?

Do analysts recommend POCI or TMCI?

Do insiders & institutionals believe in POCI or TMCI?

Which has better earnings & valuation, POCI or TMCI?

Which has more volatility & risk, POCI or TMCI?

Is POCI or TMCI more profitable?

Summary

How does Precision Optics compare to Pro-Dex?

Is PDEX or POCI more profitable?

Does the media favor PDEX or POCI?

Do analysts prefer PDEX or POCI?

Which has more risk & volatility, PDEX or POCI?

Which has better valuation and earnings, PDEX or POCI?

Do institutionals & insiders have more ownership in PDEX or POCI?

Summary

How does Precision Optics compare to Biosig Technologies?

Do analysts rate STEX or POCI?

Is STEX or POCI more profitable?

Which has more risk & volatility, STEX or POCI?

Which has higher valuation and earnings, STEX or POCI?

Does the media favor STEX or POCI?

Do insiders and institutionals have more ownership in STEX or POCI?

Summary

How does Precision Optics compare to RxSight?

Do institutionals and insiders hold more shares of POCI or RXST?

Which has more volatility and risk, POCI or RXST?

Which has preferable valuation and earnings, POCI or RXST?

Is POCI or RXST more profitable?

Does the media refer more to POCI or RXST?

Do analysts recommend POCI or RXST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

POCI vs. The Competition

Precision Optics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools